On Monday, Bristol Myers Squibb (NYSE: BMY) won the dismissal of a $6.4 billion lawsuit claiming it cheated former Celgene […]
Bristol Myers Wins Dismissal of $6.4 Billion Lawsuit Over Celgene Drug Approval Delays Read More »
2seventy Bio (NASDAQ: TSVT) will discontinue enrolling patients in a late-stage study of its cell therapy Abecma, developed in partnership
2seventy Bio (NASDAQ: TSVT) Discontinues Enrollment in Key Blood Cancer Therapy Trial Read More »
Bristol-Myers Squibb (NYSE: BMY) stock jumped during intraday trading after the pharmaceutical giant announced strong second-quarter results and raised its
Bristol-Myers Squibb (NYSE: BMY) Stock Soars on Q2 Earnings Beat, Raised Guidance Read More »
Bristol-Myers Squibb Company (NYSE: BMY) shares moved higher after the company issued better-than-expected adjusted earnings and revenue growth guidance for
Bristol-Myers Squibb Company (NYSE: BMY) Stock Gains on Upbeat Full-Year 2024 Outlook Read More »
